Continued here: Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024)
Continued here: Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024)
Original post: CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup
Read the original here: Medigene Presents Unique Approach for Use of Optimal T Cell Receptors in TCR-Guided Modalities at Cell 2024
Follow this link: Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024
Read the original: Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for...
Here is the original post: Ardelyx Responds to District Court Decision Granting Motion to Dismiss
Read more from the original source: Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid...
More here: Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the...
More here: Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued...
See the rest here: Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting
Recent Comments